Obesity and COVID-19 Pandemics: Epidemiology, Mechanisms, and Management

References

• Coronavirus disease (covid-19) situation reports (no date) World Health Organization. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed December 17, 2023.
   Google Scholar
• Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862. doi:10.1136/bmj.m3862
   PubMedGoogle Scholar
• Kim L, Garg S, O’Halloran A, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis. 2021;72(9):e206–e14. doi:10.1093/cid/ciaa1012
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland CA, Mehta N, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021;374:n2244. doi:10.1136/bmj.n2244
   PubMed Web of Science ®Google Scholar
• Thakur B, Dubey P, Benitez J, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep. 2021;11(1):8562. doi:10.1038/s41598-021-88130-w
   PubMed Web of Science ®Google Scholar
• Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782–792. doi:10.1016/S2213-8587(20)30238-2
   PubMed Web of Science ®Google Scholar
• Batabyal R, Freishtat N, Hill E, Rehman M, Freishtat R, Koutroulis I. Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics. Int J Obes. 2021;45(6):1163–1169. doi:10.1038/s41366-021-00804-7
   Web of Science ®Google Scholar
• Costa FF, Rosario WR, Ribeiro Farias AC, de Souza RG, Duarte Gondim RS, Barroso WA. Metabolic syndrome and COVID-19: an update on the associated comorbidities and proposed therapies. Diabetes Metab Syndr. 2020;14(5):809–814. doi:10.1016/j.dsx.2020.06.016
   PubMed Web of Science ®Google Scholar
• Dhama K, Nainu F, Frediansyah A, et al. Global emerging Omicron variant of SARS-CoV-2: impacts, challenges and strategies. J Infect Public Health. 2023;16(1):4–14. doi:10.1016/j.jiph.2022.11.024
   PubMed Web of Science ®Google Scholar
• Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021;9(6):350–359. doi:10.1016/S2213-8587(21)00089-9
   PubMed Web of Science ®Google Scholar
• Obesity and overweight (no date) World Health Organization. Available from: https://www.who.int/zh/news-room/fact-sheets/detail/obesity-and-overweight. Accessed December 17, 2023.
   Google Scholar
• Anderson MR, Shashaty MGS. Impact of Obesity in Critical Illness. Chest. 2021;160(6):2135–2145. doi:10.1016/j.chest.2021.08.001
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the oxford royal college of general practitioners research and surveillance centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020;20(9):1034–1042. doi:10.1016/S1473-3099(20)30371-6
   PubMed Web of Science ®Google Scholar
• Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21(11):e13128. doi:10.1111/obr.13128
   PubMed Web of Science ®Google Scholar
• Yang J, Tian C, Chen Y, Zhu C, Chi H, Li J. Obesity aggravates COVID-19: an updated systematic review and meta-analysis. J Med Virol. 2021;93(5):2662–2674. doi:10.1002/jmv.26677
   PubMed Web of Science ®Google Scholar
• Juthani PV, Gupta A, Borges KA, et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021;21(11):1485–1486. doi:10.1016/S1473-3099(21)00558-2
   PubMed Web of Science ®Google Scholar
• Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17(3):135–149. doi:10.1038/s41574-020-00462-1
   PubMed Web of Science ®Google Scholar
• Huang Y, Lu Y, Huang YM, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism. 2020;113:154378. doi:10.1016/j.metabol.2020.154378
   PubMed Web of Science ®Google Scholar
• Foldi M, Farkas N, Kiss S, et al. Obesity is a risk factor for developing critical condition in COVID-19 patients: a systematic review and meta-analysis. Obes Rev. 2020;21(10):e13095. doi:10.1111/obr.13095
   PubMed Web of Science ®Google Scholar
• Poly TN, Islam MM, Yang HC, et al. Obesity and mortality among patients diagnosed with COVID-19: a systematic review and meta-analysis. Front Med. 2021;8:620044. doi:10.3389/fmed.2021.620044
   Web of Science ®Google Scholar
• Soeroto AY, Soetedjo NN, Purwiga A, et al. Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: a systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14(6):1897–1904. doi:10.1016/j.dsx.2020.09.029
   PubMed Web of Science ®Google Scholar
• Malik P, Patel U, Patel K, et al. Obesity a predictor of outcomes of COVID-19 hospitalized patients-A systematic review and meta-analysis. J Med Virol. 2021;93(2):1188–1193. doi:10.1002/jmv.26555
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang L, Liu J, Fu S, Zhou L, Wang Y. Obesity or increased body mass index and the risk of severe outcomes in patients with COVID-19: a protocol for systematic review and meta-analysis. Medicine. 2022;101(1):e28499. doi:10.1097/MD.0000000000028499
   PubMed Web of Science ®Google Scholar
• Bridger Staatz C, Bann D, Ploubidis GB, Goodman A, Silverwood RJ. Age of first overweight and obesity, COVID-19 and long COVID in two British birth cohorts. J Epidemiol Glob Health. 2023;13(1):140–153. doi:10.1007/s44197-023-00093-5
   PubMed Web of Science ®Google Scholar
• Diamantis DV, Karatzi K, Kantaras P, et al. Prevalence and socioeconomic correlates of adult obesity in Europe: the Feel4Diabetes study. Int J Environ Res Public Health. 2022;19(19):12572. doi:10.3390/ijerph191912572
   PubMed Web of Science ®Google Scholar
• van Diepen RJ, van Erpecum CL, Tabak D, van Zon SKR, Bültmann U, Smidt N. Neighborhood socioeconomic differences in BMI: the role of fast-food outlets and physical activity facilities. Obesity. 2023;31(2):506–514. doi:10.1002/oby.23617
   PubMed Web of Science ®Google Scholar
• Allen J. The indirect effects of food insecurity on obesogenic environments. Front Public Health. 2023;10:1052957. doi:10.3389/fpubh.2022.1052957
   PubMed Web of Science ®Google Scholar
• De Lorenzo A, Cenname G, Marchetti M, et al. Social inequalities and nutritional disparities: the link between obesity and COVID-19. Eur Rev Med Pharmacol Sci. 2022;26(1):320–339. doi:10.26355/eurrev_202201_27784
   PubMed Web of Science ®Google Scholar
• Marques MB, Langouche L. Endocrine, metabolic, and morphologic alterations of adipose tissue during critical illness. Crit Care Med. 2013;41(1):317–325. doi:10.1097/CCM.0b013e318265f21c
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Wadden TA, Longo DL. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254–266. doi:10.1056/NEJMra1514009
   PubMed Web of Science ®Google Scholar
• Park JB, Kim DH, Lee H, et al. Obesity and metabolic health status are determinants for the clinical expression of hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2020;27(17):1849–1857. doi:10.1177/2047487319889714
   PubMed Web of Science ®Google Scholar
• Kayser B, Verges S. Hypoxia, energy balance, and obesity: an update. Obes Rev. 2021;22(Suppl 2):e13192.
   PubMedGoogle Scholar
• Zhang S, Zhang J, Wang C, et al. COVID19 and ischemic stroke: mechanisms of hypercoagulability (Review). Int J Mol Med. 2021;47(3). doi:10.3892/ijmm.2021.4854
   Web of Science ®Google Scholar
• Onder G, Palmieri L, Vanacore N, Giuliano M, Brusaferro S; Italian National Institute of Health C-MG. Nonrespiratory complications and obesity in patients dying with COVID-19 in Italy. Obesity. 2021;29(1):20–23. doi:10.1002/oby.23007
   PubMed Web of Science ®Google Scholar
• Nimkar A, Naaraayan A, Hasan A, et al. Incidence and risk factors for acute kidney injury and its effect on mortality in patients hospitalized from COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2020;4(6):687–695. doi:10.1016/j.mayocpiqo.2020.07.003
   PubMedGoogle Scholar
• Xie J, Prats-Uribe A, Feng Q, et al. Clinical and genetic risk factors for acute incident venous thromboembolism in ambulatory patients with COVID-19. JAMA Intern Med. 2022;182(10):1063. doi:10.1001/jamainternmed.2022.3858
   PubMed Web of Science ®Google Scholar
• Muscogiuri G, Barrea L, Verde L, Vetrani C, Savastano S, Colao A. The ”identikit” of subject with obesity and COVID-19 vaccine breakthrough. EXCLI J. 2022;21:687–694. doi:10.17179/excli2022-4864
   PubMed Web of Science ®Google Scholar
• Watanabe M, Balena A, Tuccinardi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38(1):e3465. doi:10.1002/dmrr.3465
   PubMed Web of Science ®Google Scholar
• Epsi NJ, Richard SA, Laing ED, et al. Clinical, immunological, and virological SARS-CoV-2 phenotypes in obese and nonobese military health system beneficiaries. J Infect Dis. 2021;224(9):1462–1472. doi:10.1093/infdis/jiab396
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389
   PubMed Web of Science ®Google Scholar
• Maltezou HC, Raftopoulos V, Vorou R, et al. Association between upper respiratory tract viral load, comorbidities, disease severity, and outcome of patients with SARS-CoV-2 infection. J Infect Dis. 2021;223(7):1132–1138. doi:10.1093/infdis/jiaa804
   PubMed Web of Science ®Google Scholar
• Freuer D, Linseisen J, Meisinger C. Impact of body composition on COVID-19 susceptibility and severity: a two-sample multivariable Mendelian randomization study. Metabolism. 2021;118:154732. doi:10.1016/j.metabol.2021.154732
   PubMed Web of Science ®Google Scholar
• Behazin N, Jones SB, Cohen RI, Loring SH. Respiratory restriction and elevated pleural and esophageal pressures in morbid obesity. J Appl Physiol. 2010;108(1):212–218. doi:10.1152/japplphysiol.91356.2008
   PubMed Web of Science ®Google Scholar
• Chandarana H, Dane B, Mikheev A, Taffel MT, Feng Y, Rusinek H. Visceral adipose tissue in patients with COVID-19: risk stratification for severity. Abdom Radiol. 2021;46(2):818–825. doi:10.1007/s00261-020-02693-2
   PubMed Web of Science ®Google Scholar
• Pepin JL, Timsit JF, Tamisier R, Borel JC, Levy P, Jaber S. Prevention and care of respiratory failure in obese patients. Lancet Respir Med. 2016;4(5):407–418. doi:10.1016/S2213-2600(16)00054-0
   PubMed Web of Science ®Google Scholar
• Busetto L, Enzi G, Inelmen EM, et al. Obstructive sleep apnea syndrome in morbid obesity: effects of intragastric balloon. Chest. 2005;128(2):618–623. doi:10.1378/chest.128.2.618
   PubMed Web of Science ®Google Scholar
• Kress JP, Pohlman AS, Alverdy J, Hall JB. The impact of morbid obesity on oxygen cost of breathing (VO(2RESP)) at rest. Am J Respir Crit Care Med. 1999;160(3):883–886. doi:10.1164/ajrccm.160.3.9902058
   PubMed Web of Science ®Google Scholar
• Steier J, Jolley CJ, Seymour J, Roughton M, Polkey MI, Moxham J. Neural respiratory drive in obesity. Thorax. 2009;64(8):719–725. doi:10.1136/thx.2008.109728
   PubMed Web of Science ®Google Scholar
• Masa JF, Pepin JL, Borel JC, Mokhlesi B, Murphy PB, Sanchez-Quiroga MA. Obesity hypoventilation syndrome. Eur Respir Rev. 2019;28(151):180097. doi:10.1183/16000617.0097-2018
   PubMed Web of Science ®Google Scholar
• Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 2015;3(3):207–215. doi:10.1016/S2213-8587(14)70134-2
   PubMed Web of Science ®Google Scholar
• Kanneganti TD, Dixit VD. Immunological complications of obesity. Nat Immunol. 2012;13(8):707–712. doi:10.1038/ni.2343
   PubMed Web of Science ®Google Scholar
• Morais AHA, Passos TS, de Lima Vale SH, da Silva Maia JK, Maciel BLL. Obesity and the increased risk for COVID-19: mechanisms and nutritional management. Nutr Res Rev. 2021;34(2):209–221. doi:10.1017/S095442242000027X
   PubMed Web of Science ®Google Scholar
• Moreno-Fernandez J, Ochoa J, Ojeda ML, Nogales F, Carreras O, Díaz-Castro J. Inflammation and oxidative stress, the links between obesity and COVID-19: a narrative review. J Physiol Biochem. 2022;78(3):581–591. doi:10.1007/s13105-022-00887-4
   PubMed Web of Science ®Google Scholar
• Bahr I, Spielmann J, Quandt D, Kielstein H. Obesity-associated alterations of natural killer cells and immunosurveillance of cancer. Front Immunol. 2020;11:245. doi:10.3389/fimmu.2020.00245
   PubMed Web of Science ®Google Scholar
• O’Shea D, Corrigan M, Dunne MR, et al. Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection. Int J Obes. 2013;37(11):1510–1513. doi:10.1038/ijo.2013.16
   Web of Science ®Google Scholar
• Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25(1):141–151. doi:10.1038/s41591-018-0221-5
   PubMed Web of Science ®Google Scholar
• Farnsworth CW, Schott EM, Benvie A, et al. Exacerbated staphylococcus aureus foot infections in obese/diabetic mice are associated with impaired germinal center reactions, Ig class switching, and humoral immunity. J Immunol. 2018;201(2):560–572. doi:10.4049/jimmunol.1800253
   PubMed Web of Science ®Google Scholar
• Al Heialy S, Hachim MY, Senok A, et al. Regulation of angiotensin- converting Enzyme 2 in obesity: implications for COVID-19. Front Physiol. 2020;11:555039. doi:10.3389/fphys.2020.555039
   PubMed Web of Science ®Google Scholar
• Al-Benna S. Association of high level gene expression of ACE2 in adipose tissue with mortality of COVID-19 infection in obese patients. Obes Med. 2020;19:100283. doi:10.1016/j.obmed.2020.100283
   Google Scholar
• Makhoul E, Aklinski JL, Miller J, et al. A review of COVID-19 in relation to metabolic syndrome: obesity, hypertension, diabetes, and dyslipidemia. Cureus. 2022;14(7):e27438. doi:10.7759/cureus.27438
   PubMed Web of Science ®Google Scholar
• Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016–35 e19. doi:10.1016/j.cell.2020.04.035
   PubMed Web of Science ®Google Scholar
• Hennighausen L, Lee HK. Activation of the SARS-CoV-2 receptor Ace2 by cytokines through pan JAK-STAT enhancers. SSRN. 2020;3601827. doi:10.2139/ssrn.3601827
   PubMedGoogle Scholar
• Kawasaki N, Asada R, Saito A, Kanemoto S, Imaizumi K. Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue. Sci Rep. 2012;2(1):799. doi:10.1038/srep00799
   PubMed Web of Science ®Google Scholar
• Amen OM, Sarker SD, Ghildyal R, Arya A. Endoplasmic reticulum stress activates unfolded protein response signaling and mediates inflammation, obesity, and cardiac dysfunction: therapeutic and molecular approach. Front Pharmacol. 2019;10:977. doi:10.3389/fphar.2019.00977
   PubMed Web of Science ®Google Scholar
• Ha DP, Van Krieken R, Carlos AJ, Lee AS. The stress-inducible molecular chaperone GRP78 as potential therapeutic target for coronavirus infection. J Infect. 2020;81(3):452–482. doi:10.1016/j.jinf.2020.06.017
   PubMed Web of Science ®Google Scholar
• Michalia M, Kompoti M, Koutsikou A, et al. Diabetes mellitus is an independent risk factor for ICU-acquired bloodstream infections. Intensive Care Med. 2009;35(3):448–454. doi:10.1007/s00134-008-1288-0
   PubMed Web of Science ®Google Scholar
• Wu J, Huang J, Zhu G, et al. Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study. BMJ Open Diabetes Res Care. 2020;8(1):e001476. doi:10.1136/bmjdrc-2020-001476
   PubMed Web of Science ®Google Scholar
• Yang P, Wang N, Wang J, Luo A, Gao F, Tu Y. Admission fasting plasma glucose is an independent risk factor for 28-day mortality in patients with COVID-19. J Med Virol. 2021;93(4):2168–2176. doi:10.1002/jmv.26608
   PubMed Web of Science ®Google Scholar
• Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813–821. doi:10.1177/1932296820924469
   PubMedGoogle Scholar
• Mehdipour AR, Hummer G. Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike. Proc Natl Acad Sci U S A. 2021;118(19):e2100425118.
   PubMed Web of Science ®Google Scholar
• Laviada-Molina HA, Leal-Berumen I, Rodriguez-Ayala E, Bastarrachea RA. Working hypothesis for glucose metabolism and sars-cov-2 replication: interplay Between the Hexosamine Pathway and Interferon RF5 triggering hyperinflammation. Role of BCG vaccine? Front Endocrinol. 2020;11:514. doi:10.3389/fendo.2020.00514
   PubMed Web of Science ®Google Scholar
• Ni SJ, Gao JL, Shen SS. 倪苏婕,高健林,沈树泉.肥胖和高甘油三酯血症与重症新型冠状病毒肺炎及其死亡相关联的临床证据及可能机制 [Obesity and hypertriglyceridemia: high risks for disease severity and mortality in COVID-19 patients]. Sheng Li Xue Bao. 2022;74(5):783–791. Chinese.
   PubMedGoogle Scholar
• Qin C, Minghan H, Ziwen Z, Yukun L. Alteration of lipid profile and value of lipids in the prediction of the length of hospital stay in COVID-19 pneumonia patients. Food Sci Nutr. 2020;8(11):6144–6152. doi:10.1002/fsn3.1907
   PubMed Web of Science ®Google Scholar
• Zhong P, Wang Z, Du Z. Serum triglyceride levels and related factors as prognostic indicators in COVID-19 patients: a retrospective study. Immun Inflamm Dis. 2021;9(3):1055–1060. doi:10.1002/iid3.469
   PubMed Web of Science ®Google Scholar
• Caricchio R, Gallucci M, Dass C, et al. Preliminary predictive criteria for COVID-19 cytokine storm. Ann Rheum Dis. 2021;80(1):88–95. doi:10.1136/annrheumdis-2020-218323
   PubMed Web of Science ®Google Scholar
• Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/angiotensin 1–7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118(8):1313–1326. doi:10.1161/CIRCRESAHA.116.307708
   PubMed Web of Science ®Google Scholar
• Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol. 2020;10:317. doi:10.3389/fcimb.2020.00317
   PubMed Web of Science ®Google Scholar
• Sanchis-Gomar F, Lavie CJ, Mehra MR, Henry BM, Lippi G. Obesity and outcomes in COVID-19: when an epidemic and pandemic collide. Mayo Clin Proc. 2020;95(7):1445–1453. doi:10.1016/j.mayocp.2020.05.006
   PubMed Web of Science ®Google Scholar
• Mori J, Patel VB, Ramprasath T, et al. Angiotensin 1–7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol. 2014;306(8):F812–F821. doi:10.1152/ajprenal.00655.2013
   PubMed Web of Science ®Google Scholar
• Patel VB, Mori J, McLean BA, et al. ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity. Diabetes. 2016;65(1):85–95. doi:10.2337/db15-0399
   PubMed Web of Science ®Google Scholar
• Yasue S, Masuzaki H, Okada S, et al. Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens. 2010;23(4):425–431. doi:10.1038/ajh.2009.263
   PubMed Web of Science ®Google Scholar
• Larsson A, Lipcsey M, Hultstrom M, Frithiof R, Eriksson M. Plasma leptin is increased in intensive care patients with COVID-19-an investigation performed in the PronMed-Cohort. Biomedicines. 2021;10(1):4. doi:10.3390/biomedicines10010004
   PubMed Web of Science ®Google Scholar
• Di Filippo L, De Lorenzo R, Sciorati C, et al. Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19. Diabetes Metab. 2021;47(6):101268. doi:10.1016/j.diabet.2021.101268
   PubMed Web of Science ®Google Scholar
• Jung CH, Kim MS. Molecular mechanisms of central leptin resistance in obesity. Arch Pharm Res. 2013;36(2):201–207. doi:10.1007/s12272-013-0020-y
   PubMed Web of Science ®Google Scholar
• Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. 2017;18(6):1321. doi:10.3390/ijms18061321
   PubMed Web of Science ®Google Scholar
• Choi HM, Doss HM, Kim KS. Multifaceted physiological roles of adiponectin in inflammation and diseases. Int J Mol Sci. 2020;21(4):1219.
   PubMed Web of Science ®Google Scholar
• Kearns SM, Ahern KW, Patrie JT, Horton WB, Harris TE, Kadl A. Reduced adiponectin levels in patients with COVID-19 acute respiratory failure: a case-control study. Physiol Rep. 2021;9(7):e14843. doi:10.14814/phy2.14843
   PubMed Web of Science ®Google Scholar
• Zeigler Z. COVID-19 self-quarantine and weight gain risk factors in adults. Curr Obes Rep. 2021;10(3):423–433. doi:10.1007/s13679-021-00449-7
   PubMed Web of Science ®Google Scholar
• Ho FK, Celis-Morales CA, Gray SR, et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open. 2020;10(11):e040402. doi:10.1136/bmjopen-2020-040402
   PubMed Web of Science ®Google Scholar
• Lino RS, Silva MSP, Jesus DS, et al. Molecular aspects of COVID-19 and its relationship with obesity and physical activity: a narrative review. Sao Paulo Med J. 2023;141(1):78–86. doi:10.1590/1516-3180.2021.1038.r1.06072022
   PubMed Web of Science ®Google Scholar
• Sattar N, Valabhji J. Obesity as a risk factor for severe COVID-19: summary of the best evidence and implications for health care. Curr Obes Rep. 2021;10(3):282–289. doi:10.1007/s13679-021-00448-8
   PubMed Web of Science ®Google Scholar
• Dissanayake H. COVID-19 and metabolic syndrome. Best Pract Res Clin Endocrinol Metab. 2023;37(4):101753. doi:10.1016/j.beem.2023.101753
   PubMed Web of Science ®Google Scholar
• Dohet F, Loap S, Menzel A, et al. Obesity considerations during the COVID-19 outbreak. Int J Vitam Nutr Res. 2022;92(1):67–79. doi:10.1024/0300-9831/a000695
   PubMed Web of Science ®Google Scholar
• Hauner H. The COVID-19 pandemic: challenges for obesity management - a call for providing reliable data and solutions. Obes Facts. 2022;15(3):303–304. doi:10.1159/000524424
   PubMed Web of Science ®Google Scholar
• Melamed OC, Selby P, Taylor VH. Mental health and obesity during the COVID-19 pandemic. Curr Obes Rep. 2022;11(1):23–31. doi:10.1007/s13679-021-00466-6
   PubMed Web of Science ®Google Scholar